Arrowhead just unlocked Australia for REDEMPLO, but the bigger RNAi test starts now

By Pallavi Madhiraju on May 3, 2026   Pharma & Biotech  

Arrowhead has regulatory momentum in rare lipid disease. The harder test is turning REDEMPLO approval into durable global uptake.